Citations

Clear

2960 citation(s) found for "Kim, In-Ho".

Influence of brief carbon dioxide inhalation on acute exercise performance and recovery: A pilot study
Yeo, Dongwook , Schwartz, Jesse C., Johnson, Bruce D. , Kim, Chul‐Ho

Mayo Clinic

Physiological Reports | June 20, 2026 | Volume: 14 | Issue: 12 | Pages: No page available

10.14814/phy2.70893 | PMID 42322004 Get It

Abstract Brief inhalation of carbon dioxide (CO 2 ) has been proposed to counteract transient hypocapnia by enhancing oxygen unloading, vasodilation, and sympathetic modulation. Despite these potential ergogenic mechanisms, CO 2 has rarely been investigated in the exercise context. The present study investigated whether brief CO 2 inhalation (iCO 2 ) influences performance and recovery during high‐intensity interval exercise. Nine healthy adults completed two randomized, single‐blinded crossover trials of repeated cycling intervals at 85% peak work rate until volitional exhaustion or cadence dropped below 60 rpm, with a minimum 2‐min interval duration required and 3‐min active recovery between bouts. Participants inhaled 5% CO 2 or room air (15 breaths) before and after each exercise bout. Gas exchange, cardiovascular responses, and perceived exertion were assessed. Total exercise time was similar between trials; however, participants completed more intervals with iCO 2 . During the first interval, iCO 2 increased exercise duration and VO 2 . At matched exercise time, perceived exertion and dyspnea were lower with iCO 2 . During recovery, systolic blood pressure was lower and heart rate was higher following iCO 2 . Brief iCO 2 improved first‐interval performance, altered cardiovascular recovery, and reduced perceptual strain but did not extend overall exercise duration. These findings suggest iCO 2 may transiently modulate tolerance and autonomic‐vascular responses during high‐intensity interval exercise.
A soluble bi-specific fusion protein for the improved expansion of human CD8 + CAR-T cells
Law, Jaclyn C., Matus, Esther I., Mina, Pooja R., Sparkes, Amanda , Asokumar, Navin, Trottier, Shannon , Kim, Gloria B. , Garie¬¥py, Jean, Matus, Esther I., Mina, Pooja Rani , Gariépy, Jean

Mayo Clinic

No container title available | June 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.16.26355813 Get It

Abstract The success of Chimeric Antigen Receptor (CAR) T cell therapy is heavily dependent on the quality of the final cellular product. Current expansion protocols often rely on reagents that require removal from cell culture media, posing logistical challenges in manufacturing, and can also lead to terminal differentiation. Here, we evaluate the use of a soluble, bead-free T cell activator, T cell expansion protein (T-CEP), as a streamlined alternative for generating potent CAR-T cells. Human T cells were activated with T-CEP or known T cell activators (Dynabeads and TransAct) and transduced with either CD19 or interleukin-13 (IL-13) mutein (tetravariant-13; TV-13)-based CAR lentiviral vectors. Our results demonstrate that T-CEP supports robust CAR-T cell expansion and achieves transduction efficiencies comparable to commercial reagents for both types of CAR-T cells. Notably, T-CEP significantly favored the expansion of CD8 + T cells, yielding an enhanced CD27 + phenotype and a lower CD4:CD8 ratio compared to TransAct. Cytotoxicity assays confirmed that T-CEP-expanded CAR-T cells possess cytolytic function equivalent to commercial reagents for both CARs, while exhibiting lower levels of inflammatory cytokine secretion. In summary, T-CEP represents a competitive alternative to existing expansion agents, as it does not require its removal during CAR-T manufacturing and generates a CD8 + dominant, less-differentiated phenotype without compromising efficacy. Key Points T-CEP is a soluble, bead-free activator that streamlines CAR-T manufacturing by eliminating the need for reagent removal from cultures. T-CEP consistently yields a desirable CD27 + CD8 + phenotype with a moderate inflammatory profile compared to industry-standard expanders.
Reversible White Matter Diffusion Restriction Lesion in Pediatric Cerebral Malaria
Lai, Sammie , Taskin, Didem, Hana, Leticia Schaefer Abu, Kim, Jeong-A, Schaefer Abu Hana, Leticia

Mayo Clinic

Neurology | June 18, 2026 | Volume: 107 | Issue: 2 | Pages: No page available

10.1212/wnl.0000000000218221 | PMID 42314079 Get It

Development of a Core Outcome Domain Set for Facial Aging
Dirr, McKenzie A. , Ahmed, Areeba, Schlessinger, Daniel I., Lazaro-Camp, Vanessa, Smith, SJ, Gullapalli, Thanvi, Dragovic, Doroteja, Chang, Joycie, Zhang, Elizabeth, Alam, Murad, Group, Facial Aging Core Outcome Domain Set Study, Anvery, Noor , Kang, Bianca Y. , Wong, Clarissa, Iyengar, Sanjana, Yanes, Arianna F. , Cotseones, Jill, Ashchyan, Hovik J. , Patel, P. M., Sheikh, Umar A., Franklin, Matthew , Hanna, Courtney, Chiren, Sarah G., Schmitt, J, Furlan, Karina C., Alexiades, Macrene, Alhusayen, Raed, Alster, Tina S. , Beer, Kenneth, Bertucci, Vince , Bloom, Jason D. , Briceño, César A., Bucay, Vivian, Butterwick, Kimberly J., Hugues, Cartier, Casabona, Gabriela, Connolly, Karen , Cox, Sue Ellen , Darmanescu, Monica, Boulle, Koenraad De , Desai, Shraddha, Donofrio, Lisa, Dover, Jeffrey S., Draelos, Zoe, Eisen, Daniel B. , El-Domyati, Moetaz, El-Garem, Yehia, Fischer, John, Fitzgerald, Rebecca, GALADARI, Hassan, Gladstone, Hayes B., Goldman, Mitchel P., Goodman, Greg J., Hanke, C. William , Humphrey, Shannon, Ibrahim, Sherrif F., Jagdeo, Jared, Karen, Julie, Kauvar, Arielle, Ag, Kibbi, KIM, JENNY, Lacerda, D T D, Lask, G, Lopez, Grace M., Lupo, Mary P. , Mariwalla, Kavita , Matarasso, Seth, Mekokishvili, L, Narins, Rhoda S., Ogilvie, P, Orringer, Jeffrey S. , Osaki, Tammy H. , Ozog, David, Pacheco, Theresa, Polder, Kristel, Rossi, Anthony M, Sadick, Neil, Saedi, Nazanin, Schlessinger, Joel, Sharad, Jaishree , Shenoy, SuchitraM, Sinclair, Rd, Solish, Nowell, Piansay‐Soriano, Miriam Emily , Sulyman, Omotara , Szeimies, Rolf‐Markus , Tanzi, Elizabeth L., Taub, Amy Forman , Taylor, Mark B., Thomas, J. Regan, Torezan, Luis, Tosti, Antonella, Touma, Dany, Almeida, Ada Regina Trindade de , Vedamurthy, Maya , Viana, Giovanni, Waldman, Abigail, Weinkle, Susan, Weiss, Robert, Poon, Emily, Cartee, Todd V. , Sobanko, Joseph F. , Eisen, Daniel B. , Ahmed, Areeba , Schlessinger, Daniel Isaac , Lazaro-Camp, Vanessa J, Christensen, Rachel E. , Ibrahim, Sarah A. , Cotseones, J.K., Umar, Sheikh Ahmad , Furlan, Karina Colossi , Alexiades, Macrene , Alhusayen, Raed , Beer, Kenneth Robert, Briceño, César Augusto , Bucay, Vivian , Casabona, Gabriela , Cotofana, Sebastian , Desai, Shraddha , Dover, Jeffrey S. , Draelos, Zoe Diana , Eisen, Daniel B., El-Domyati, Moetaz M. , El-Garem, Yehia, Fitzgerald, Rebecca, Friedmann, Daniel P. , Galadari, Hassan , Gladstone, Hayes B., Goldman, Mitchel P. , Goodman, Greg , Green, Jeremy B. , Halachmi, Shlomit , Humphrey, Shannon , Jagdeo, Jared R. , Jiang, Shang I. Brian , Kauvar, Arielle N.B. , Kibbi, Abdul‐Ghani , Kim, John V. S., LASK, GARY P., Matarasso, Seth L., Narins, Rhoda S., Ogilvie, Patricia , Osaki, Tammy H. , Pacheco, Theresa , Polder, Kristel D., Saedi, Nazanin, Shenoy, Manjunath , Sinclair, Rod, Solish, Nowell , Torezan, Luís , Tosti, Antonellá , Waldman, Abigail , Weiss, Robert, Maher, Ian A. , Kirkham, Jamie J

Mayo Clinic

JAMA Dermatology | June 17, 2026 | Volume: 162 | Issue: 8 | Pages: 829

10.1001/jamadermatol.2026.1697 | PMID 42307924 Get It

Importance Currently, there are no standardized outcome domains or measures in clinical trials for facial aging. Heterogeneity in outcome domains and measurement instruments across clinical trials creates difficulty in directly comparing interventions, determining superior therapies, and developing high-quality meta-analyses. Objective To develop a core outcome set (COS) of essential domains to be reported in clinical trials evaluating the efficacy of interventions for facial aging. Evidence Review PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials, and CINAHL were searched from September 2005 to September 2015. An updated search of the same databases was performed from September 2015 to February 2026. Studies were included if (1) they were randomized clinical trial or controlled clinical trial in design, (2) they assessed the efficacy or safety of an intervention for facial aging, (3) they were published in English, and (4) they involved human participants. Complementary sources, including patient interviews, were used to capture further relevant outcomes. Two rounds of Delphi surveys, followed by consensus meetings, were used to identify outcome domains considered most important by both patient and physician stakeholders. Findings The final COS consists of 6 outcome domains: (1) overall convenience of treatment; (2) time to return to normal work and social activity; (3) overall assessment of focused area of treatment (at the point in time when treatment is expected to provide peak benefit); (4) duration of treatment effect; (5) severity of persistent local or systemic adverse events, including pigmentary change, skin texture change, delayed healing, scarring, and serious adverse events; and (6) patient satisfaction with treatment. Conclusions and Relevance The 6 outcome domains identified through a Delphi consensus are recommended for reporting in future facial aging trials to ensure that outcomes that matter most to patients and clinicians are measured and that results are comparable across interventions.
Mitochondrial Complex I Modulator Restores Network Resilience in Advanced Alzheimer’s Disease Through Metabolic Reprogramming
Gabal, Esraa , Nguyen, Thi Kim Oanh , Kovalenko, Tetiana , Gao, Huanyao , Funk, Cory C. , Baloni, Priyanka , Trushina, Eugenia , Rappaport, Noa , Funk, Cory , Baloni, Priyanka , Trushina, Eugenia , Kovalenko, Tetiana , Rappaport, Noa

Mayo Clinic

No container title available | June 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.14.732179 | PMID 42367849 Get It

Abstract Mitochondrial dysfunction and lipid dysregulation are among the earliest abnormalities in Alzheimer’s disease (AD), yet their mechanistic interplay and therapeutic potential remain poorly understood. Here, we investigated whether restoration of mitochondrial function can reverse metabolic dysfunction and promote resilience in advanced-stage AD. Female APP/PS1 mice were treated with the brain-penetrant mitochondrial complex I (mtCI) modulator CP2 beginning at 19 months of age, when pathology and cognitive deficits were well established. To define the metabolic mechanisms underlying therapeutic response, we developed iMiceBrain , the first brain-specific genome-scale metabolic model of the mouse brain, and integrated transcriptomics, targeted metabolomics, lipidomics, and metabolic network analyses. CP2 treatment broadly reprogrammed AD-associated molecular signatures and restored pathways involved in mitochondrial function, glucose utilization, lipid metabolism, synaptic activity, and cellular stress responses. Metabolic modeling identified enhanced mitochondrial substrate flexibility, activation of fatty acid utilization, restoration of pyruvate dehydrogenase flux, and normalization of cholesterol metabolism as key features of the therapeutic response. Lipidomic analyses further demonstrated correction of disease-associated alterations in cholesteryl esters, phospholipids, and sphingolipids. Together, these findings demonstrate that mild mtCI modulation restores metabolic resilience by coordinating mitochondrial and lipid metabolism, establishing it as a disease-modifying therapeutic strategy for AD.
Caring for Transgender and Gender-diverse Parents
Kim, Hyun-Hee, Evangelinos, Eirini, Fonseca, Emrys , Cosner, Chelsea, Kim, Hyun-Hee , Cosner, Chelsea R.

Mayo Clinic

Psychiatric Annals | June 16, 2026 | Volume: 56 | Issue: 6 | Pages: No page available

10.3928/00485713-20260402-01 Get It

Transgender and gender-diverse (TGD) people comprise approximately 0.9% of adults in the United States; among them, 18% to 50% of TGD adults surveyed report being parents. Younger generations of Americans are more likely to identify as TGD, and also more likely to desire children than previous generations of TGD individuals surveyed. Despite this, TGD parents are often underrepresented in literature on parenting experiences of lesbian, gay, bisexual, transgender, and queer (LGBTQ+) parents. TGD parents experience significant mental health, physical health, and socioeconomic disparities due to gender minority stressors, and numerous barriers to reproductive care and affirming mental health care. This article presents an overview of the current literature on TGD parents, psychosocial outcomes for children of TGD parents, common clinical issues that may arise in treatment, and strategies for supporting TGD families to build resilience.
Nuclear Enlargement as a Histological Hallmark of Skeletal Muscle Aging, Revealed by Deep Learning‐Driven Analysis and Validated in Inflammatory Myopathies
Dao, Tam, Nguyen, T. , Hoang, Gia Minh , Park, Junhyeon , Jo, Yunju, Ngoc, Thach Hoang, Pho, Diep Hong, Minh, D Q, Ton, Emma Anh, LEE, S, Dũng, Vũ Chí, Kim, Jae Gwan , Ryu, Dongryeol, Kim, Jae Gwan , Dao, Tam , Jo, Yunju , Diep, Pho Hong , Minh, Dien Tran, Kim, Hyun‐Jin , Ryu, Dongryeol

Mayo Clinic

Aging Cell | June 15, 2026 | Volume: 25 | Issue: 6 | Pages: No page available

10.1111/acel.70577 | PMID 42295036 Get It

ABSTRACT Aging reshapes the architecture of human skeletal muscle, yet objective tissue‐level markers that capture this process remain limited. We combined large‐scale histology with deep learning to identify reproducible features of muscle aging and to test their biological relevance. We analyzed 974 hematoxylin–eosin whole‐slide images from a population resource using a dual‐attention convolutional neural network and an independent Mask R‐CNN model to quantify nuclear size and density, verified by manual review. The classifier distinguished young from aged muscle with high accuracy (AUC 0.91; accuracy 86.2%), and attention maps consistently highlighted nuclear enlargement and spatial disorganization as salient features. Nuclear diameter increased with age (Spearman's ρ = 0.71, p < 0.0001) across automated and manual measurements. Transcriptomes matched to the same donors showed that samples with larger nuclei were enriched for pathways related to chromatin remodeling, proteostasis, cellular senescence, mitochondrial activity, and telomere regulation, whereas smaller nuclei aligned with anti‐inflammatory and DNA repair programs. External pediatric inflammatory myopathies exhibited nuclear enlargement comparable to aged muscle, suggesting inflammation‐related premature histologic aging. These findings identify nuclear enlargement as a robust, quantifiable feature that integrates structural and molecular signatures of muscle aging. The proposed deep learning–based nuclear morphometry provides a scalable framework for tissue‐level aging biomarkers and suggests a potential “muscle aging clock” applicable to both physiological aging and disease states.
Endoscopic Ultrasound Guided Transrectal Drainage of a Nonresolving Multiloculated Rectal Abscess in a Patient With Advanced Anal Squamous Cell Carcinoma
Ingawale, Sushrut , KIM, H, Jue, Terry L., Kim, Hyun Jae

Mayo Clinic

ACG Case Reports Journal | June 12, 2026 | Volume: 13 | Issue: 6 | Pages: No page available

10.14309/crj.0000000000002176 | PMID 42292934 Get It

A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab to Prevent Relapses in Neuromyelitis Optica Spectrum Disorder (NMOSD) (P3-1.001)
Bilodeau, Philippe-Antoine, Devlin, Michael, Bhattacharyya, Shamik, Salky, Rebecca, Mendoza, Juan Sebastian, Friede, Tim, Bennett, Jeffrey, Cree, Bruce, Palace, Jacqueline, Levy, Michael, Fujihara, Kazuo, Kim, Ho Jin, Flanagan, Eoin , Matiello, Marcelo, Paul, Friedemann, Vishnevetsky, Anastasia , Bhattacharyya, Shamik , Friede, Tim , Cree, Bruce , Palace, Jacqueline , Levy, Michael , Fujihara, Kazuo , Kim, Ho Jin , Flanagan, Eoin P. , Matiello, Marcelo , Paul, Friedemann

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217044 Get It